The expanded role of the transplant pharmacist: A 10-year follow-up.

Autor:	Lichvar AB; Center for Transplantation, University of California San Diego Health, La Jolla, California, USA. Electronic address: alichvar@health.ucsd.edu., Chandran MM; Department of Pharmacy, UNC Health, Chapel Hill, North Carolina, USA., Cohen EA; Department of Transplantation, Yale New Haven Hospital, New Haven, Connecticut, USA., Crowther BR; Department of Pharmacy, University of Colorado Health, Aurora, Colorado, USA., Doligalski CT; Department of Pharmacy, UNC Health, Chapel Hill, North Carolina, USA., Condon Martinez AJ; Kidneylink, U.S. Renal Care Plano, Texas, USA., Potter LMM; Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA., Taber DJ; Division of Transplantation, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA., Alloway RR; Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Jazyk:	angličtina
Zdroj:	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2023 Sep; Vol. 23 (9), pp. 1375-1387. Date of Electronic Publication: 2023 May 04.
DOI:	10.1016/j.ajt.2023.04.032
Abstrakt:	The role of the transplant pharmacist is recognized by transplant programs, governmental groups, and professional organizations as an essential part of the transplant multidisciplinary team. This role has evolved drastically over the last decade with the advent of major advances in the science of transplantation and the growth of the field, which necessitate expanded pharmacy services to meet the needs of patients. Data now exist within all realms of the phases of care for a transplant recipient regarding the utility and benefit of a solid organ transplant (SOT) pharmacist. Furthermore, governing bodies now have the opportunity to use Board Certification in Solid Organ Transplant Pharmacotherapy as a mechanism to identify and recognize specialty knowledge and expertise within the field of SOT pharmacotherapy. The purpose of this paper is to provide an overarching review of the current and future state of SOT pharmacy while also identifying major changes to the profession, forthcoming challenges, and expected areas of growth. Competing Interests: Declaration of Competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Lisa Potter reports a relationship with Takeda Pharmaceuticals USA Inc that includes: board membership. Lisa Potter reports a relationship with Veloxis Pharmaceuticals Inc that includes: funding grants and speaking and lecture fees. David Taber reports a relationship with Veloxis Pharmaceuticals Inc that includes: board membership and funding grants. David Taber reports a relationship with Takeda Pharmaceuticals USA Inc that includes: funding grants. David Taber reports a relationship with Merk that includes: funding grants. David Taber reports a relationship with CareDx Inc that includes: funding grants. Rita Alloway reports a relationship with Bristol Myers Squibb Co that includes: funding grants. Rita Alloway reports a relationship with Nobelpharma Co Ltd that includes: funding grants. Rita Alloway reports a relationship with National Institutes of Health that includes: funding grants. Rita Alloway reports a relationship with Veloxis Pharmaceuticals Inc that includes: board membership and speaking and lecture fees. Rita Alloway reports a relationship with Sanofi that includes: speaking and lecture fees. The authors A. B. Lichvar, M. M. Chandran, B. R. Crowther, C. T. Doligalski, and A. J. C. Martinez of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. The following authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. L. M. M. Potter reported serving as an advisory board member for Takeda in Dec 2021. E. A. Cohen reported serving for the speaker bureau of Veloxis that ended in Dec 2021 and receiving an investigator-initiated research grant from Veloxis Pharmaceuticals. D. J. Taber reported serving as a board member of the Veloxis grant and advisory board, Takeda grant, Merck grant, and CareDx grant. R. R. Alloway reported BMS, Nobelpharma, Thinker NEXT grant, Veloxis advisory board, Veloxis, and Sanofi speaker bureau. (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu